Company / SG&A Expense
Pasithea Therapeutics Corp. SG&A Expense History
FY2021-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$4.5M
FY2022
5-year range
$41.0K / $4.5M
FY2021-FY2022
Trend
+10892.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$5M in FY2022.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, sg&a expense increased 10892.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.26 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $4.5M | +10892.6% |
| FY2021 | $41.0K | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026